Biogen Inc.
Biogen Inc. discovers, develops, manufactures, and delivers therapies for treating neurological and neurodegenerative diseases. The company offers TECFIDERA, VUMERITY, AVONEX, PLEGRIDY, TYSABRI, and FAMPYRA for multiple sclerosis (MS); SPINRAZA for spina…
Drug Manufacturers - General
US, Cambridge [HQ]
FA
Fundamental Analysis · Most Recent Quarter
A dedicated fundamental analysis might help you to get a quick overview
of the
financial stability. It is important to understand the
FA Algorithm
and the criterias before valuing it as a top-tier resource.
Fundamentals
Valuation
| Metric | Q4 | Q1 | Δ in % | |
|---|---|---|---|---|
| EV/EBITDA | -23.87 | 53.49 | 70.26 | |
| Graham Fair Price | 27.00 | 79.92 | 62.93 | |
| PEG | 327.47 | 0.34 | -0.08 | |
| Price/Book | -19.07 | 2.05 | 2.53 | |
| Price/Cash Flow | -89.86 | 72.16 | -711.49 | |
| Prices/Earnings | -47.20 | 19.82 | 37.54 | |
| Price/Sales | -9.78 | 14.18 | 15.71 | |
| Price/FCF | -89.86 | 72.16 | -711.49 | |
| Naive Interpretation | member | |||
01 - Valuation ·
Weak
Fundamentals
Profitability
| Metric | Q4 | Q1 | Δ in % | |
|---|---|---|---|---|
| Gross Profit Margin | -7.34 | 0.69 | 0.74 | |
| Operating Margin | 102.85 | 0.25 | 0.12 | |
| ROA | 59.19 | 0.01 | < 0.005 | |
| ROE | 0.02 | 0.03 | 53.27 | |
| ROIC | 0.01 | 0.02 | 88.74 | |
| Naive Interpretation | member | |||
02 - Profitability ·
Not Interpreted
Fundamentals
Financial Growth
| Metric | Q4 | Q1 | Δ in % | |
|---|---|---|---|---|
| Debt QOQ | -0.05 | -0.05 | -9.21 | |
| Dividends QOQ | 0.00 | 0.00 | 0.00 | |
| EBIT QOQ | 3.07 | 0.87 | -71.60 | |
| EPS QOQ | 4.66 | 0.58 | -87.65 | |
| FCF QOQ | -1.10 | 9.20 | 733.31 | |
| Revenue QOQ | -0.06 | -0.08 | -36.96 | |
| Naive Interpretation | member | |||
03 - Financial Growth ·
Weak
Fundamentals
Leverage & Liquidity
| Metric | Q4 | Q1 | Δ in % | |
|---|---|---|---|---|
| Assets Turnover | n.A. | n.A. | n.A. | |
| Days Inventory Outstanding (DIO) | 367.89 | 328.37 | -10.74 | |
| Days Sales Outstanding (DSO) | 79.20 | 81.79 | 3.27 | |
| Inventory Turnover | 0.24 | 0.27 | 12.03 | |
| Debt/Capitalization | 0.33 | 0.30 | -9.30 | |
| Quick Ratio | 0.92 | 0.95 | 4.00 | |
| Naive Interpretation | member | |||
04 - Leverage & Liquidity ·
Bad
Fundamentals
Per Share Metrics
| Metric | Q4 | Q1 | Δ in % | |
|---|---|---|---|---|
| Book Value | 102.14 | 104.77 | 2.58 | |
| Cash | 7.25 | 7.40 | 2.12 | |
| Capex | -0.45 | -0.83 | -85.05 | |
| Free Cash Flow | -0.36 | 2.98 | 718.61 | |
| Revenue | 16.47 | 15.15 | -7.99 | |
| Naive Interpretation | member | |||
05 - Per Share Metrics ·
Positive
Fundamentals
Financial Health
06 - Financial Health ·
Bad